Latigo Biotherapeutics, Inc. Common Stock (LTGO)

• Market cap: $1.23B
• 1 day: 5.26%
• 5 days: -2.86%
• 1 month: 11.78%
• 3 months: 11.78%
• 6 months: 11.78%
• Year to date: 11.78%
• 1 year: 11.78%
• 5 years: 11.78%
• 10 years: 11.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.